USA: +1 347 690-0211 | UK: +44 2032 894158 | JAPAN: +81 50 5806 9039 | Translate : 

report img

Non-Insulin Therapies for Diabetes Market By Product Type (Oral & Injectable) and By Distributor (Retail Pharmacies, Hospital Pharmacy, Online Pharmacy, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast 2021 – 2028

Covid-19

Global Non-Insulin Therapies for Diabetes Market Size, Share

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Insights

[205+ Pages Report] According to Facts and Factors, the size of the global non-insulin therapies for diabetes market was worth around 62,011 (USD Million) in 2020 and is predicted to grow to around 104,863 (USD Million) by 2028 with a compound annual growth rate (CAGR) of roughly 6.29% between 2021 and 2028. The report analyses the non-insulin therapies for diabetes market’s drivers and restraints, as well as the impact they have on-demand throughout the projection period. In addition, the report examines global opportunities in the global non-insulin therapies for diabetes market

logoMarket Overview

Diabetes affects more than 30 million people in the United States, or around one out of every ten people, according to the Centre for Disease Control and Prevention (CDC). Type 2 diabetes affects 90–95 percent of these people. In type 2 diabetes patients, the body either does not produce enough insulin or is unable to effectively utilize the insulin it produces. Non-insulin therapies are mostly used for the treatment of type 2 diabetes. Non-insulin-based medications use alternative mechanisms of action to lower blood glucose levels and keep them stable for optimal glycemic control.

The insulin category accounts for a large portion of the market in terms of pharmaceuticals. Insulin is required by about 100 million people worldwide, including all patients with Type 1 diabetes and between 10% and 25% of people with Type 2 diabetes.

logo Growth Drivers

The growing global incidence and prevalence of diabetes are expected to fuel the development of global non-insulin therapies for diabetes market. As per the International Diabetes Federation's Diabetes Atlas 2017, the overall prevalence of diabetic individuals was 425 million, with type 2 diabetes accounting for the vast majority. Non-insulin treatments are most commonly used in type 2 diabetes, which accounts for a sizable proportion of all diabetes cases globally. According to the WHO 2017 report, diabetes is one of the top three causes of death among non-communicable diseases worldwide. This is the primary factor driving the growth of the worldwide non-insulin therapies for diabetes market.

Non-Insulin Therapies for Diabetes Market

The global non-insulin therapies for diabetes market is growing due to the rising demand for combination therapy and significant improvements in diabetes. For the treatment of type 2 diabetes, combination therapies such as the administration of anti-hyperglycemic medications alone or in addition with insulin are administered. Moreover, on the demand side, the rising number of individuals with type 2 diabetes is the key driver for the global adoption of various non-insulin therapies.

Established players, on the other hand, are putting modern technologies into their products. These technologies can anticipate, monitor, and adjust to the user's needs. These technological advancements give producers a competitive advantage over their competitors, allowing them to maintain a hold on the global market for non-insulin therapies for diabetes.

logoReport Scope

Report Attribute

Details

Market Size in 2020

USD 62,011 Million

Projected Market Size in 2028

USD 104,863 Million

CAGR Growth Rate

6.29% CAGR

Base Year

2020

Forecast Years

2021-2028

Key Market Players

Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Novo Nordisk, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, AstraZeneca, Merck and Company, Sanofi Aventis, Eli Lilly and Company, Pfizer, Novartis AG, Takeda Pharmaceuticals., among others

Key Segment

By Product Type, By Distributor, and By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logoRegional Landscape

The North American market is expected to generate roughly USD 35,080 million in revenue by the end of the forecast period. The enormous deployment of non-insulin therapy for treating diabetes in nations like the United States is credited with the market's expansion in North America.

According to the International Diabetes Federation (IDF), the United States saw roughly 17,100 new cases of diabetes in 2017. Due to the rising diabetes burden in China and India, which together have over 180 million diabetic patients, Asia Pacific is one of the most lucrative regions. According to the American Diabetes Association (ADA), between 2000 and 2035, the incidence of type 2 diabetes in South Asia is expected to rise by more than 150%.

logoRecent Development

Players are using strategies like partnerships, collaborations, and mergers to combat the competitive and fragmented structure of the global non-insulin therapies for diabetes market. Players can use these techniques to expand their business globally. Furthermore, these tactics allow businesses to reach out to previously untapped markets that can be profitable. These tactics also enable firms to gather resources that will help them sustain and succeed in the global non-insulin therapies for diabetes market.

logoCompetitive Landscape

Some of the key players operating in the global non-insulin therapies for diabetes market are:

Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Novo Nordisk, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, AstraZeneca, Merck and Company, Sanofi Aventis, Eli Lilly and Company, Pfizer, Novartis AG, and Takeda Pharmaceuticals.

The global non-insulin therapies for diabetes market is segmented as follows:

logoBy Product Type Segment Analysis

  • Oral
  • Injectable

logoBy Distributor Segment Analysis

  • Retail Pharmacies
  • Hospital Pharmacy
  • Online Pharmacy
  • Others

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Reunion
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Southeast Asia
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Covid-19

Non-Insulin Therapies for Diabetes Market

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Major Market Players

  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Novo Nordisk
  • GlaxoSmithKline
  • F. Hoffmann-La Roche Ltd.
  • Janssen Pharmaceuticals
  • AstraZeneca
  • Merck and Company
  • Sanofi Aventis
  • Eli Lilly and Company
  • Pfizer
  • Novartis AG
  • Takeda Pharmaceuticals

Frequently Asked Questions

The rising global incidence and prevalence of diabetes are likely to drive the global non-insulin therapies for diabetes market forward. Non-insulin therapy is primarily utilized in type 2 diabetes, which accounts for approximately 90% of all diabetes cases worldwide. Diabetes has a large economic impact worldwide, which is predicted to grow significantly over the next few years.
According to the Facts & Factors report, the global non-insulin therapies for diabetes market was worth around USD 62,011 Million in 2020 and is predicted to grow to around USD 104,863 Million by 2028, with a CAGR of roughly 6.29% between 2021 and 2028.
The North American market is expected to generate roughly USD 35,080 million in revenue by the end of the forecast period. The enormous deployment of non-insulin therapy for treating diabetes in nations like the United States is credited with the market's expansion in North America.
Some of the key players operating in the global non-insulin therapies for diabetes market are: Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Novo Nordisk, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, AstraZeneca, Merck and Company, Sanofi Aventis, Eli Lilly and Company, Pfizer, Novartis AG, and Takeda Pharmaceuticals.
why choose fnf
key questions answers

Related Reports

report img

Cold Plasma Market Report 2022-2028

[201+ Pages Report] According to Facts and Factors, the global cold plasma market was worth USD 1.8 billion in 2021 and is expected to grow to USD 3.5 billion by 2028, growing at a 16.2% CAGR between 2022 and 2028. The global cold plasma market report provides a comprehensive analysis of the marke...

Published Date : 11-May-2022 | | Category : | Pages : 201 | Format : Read more

Inquiry for Buying Request Sample
report img

Etanercept Market Report 2022-2028

[221+ Pages Report] According to Facts and Factors, during the forecast period of 2022 to 2028, the global etanercept market is estimated to develop at a compound annual growth rate (CAGR) of 3.3%. The global etanercept market was worth USD 15.5 billion in 2021, and it is anticipated to exceed USD...

Published Date : 26-Apr-2022 | | Category : | Pages : 221 | Format : Read more

Inquiry for Buying Request Sample